NFE2L2 and amyotrophic lateral sclerosis: This is the first assessment of a CNS penetrating, Nrf2 activating small molecule which has followed the recommendations on preclinical studies in ALS mouse models [31] and which has evaluated the therapeutic potential in an in vitro model of human ALS.